Turn Therapeutics

TTRX · NASDAQ

$10.47−$0.27 (−2.51%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $10.74

TTRX analyst rating

HoldConsensus of 3 analysts over the last 12 months. 67% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell1

12-month price target · 5 analysts

Average $20.40 (+94.8% upside)

Low: $10.10
Now: $10.47
High: $27.30

Upgrades and downgrades

The latest rating actions, newest first

TTRX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
LUCID CAPITAL MARKETS	Sep 24, 2026	Initiates	Buy	$24.00	36%
WBB Securities	Sep 14, 2026	Downgrade	Hold → Sell	$10.00	50%
D. Boral Capital	Mar 24, 2026	Maintains	Buy	$8.00	29%
D. Boral Capital	Jan 20, 2026	Maintains	Buy	$8.00	29%
D. Boral Capital	Dec 29, 2025	Initiates	Buy	$8.00	29%

The case for and against

Updated Jul 7, 2026

Bull case

Turn Therapeutics is a clinical-stage biotechnology and medical device development company with a strong focus on its proprietary platform technology, PermaFusion, which has shown promising results in the treatment of inflammatory skin disease. Its lead program, GX-03, is currently being evaluated for potential use as a topical treatment for moderate-to-severe eczema, and if successful, could tap into a large market with an estimated 500,000+ adults and 200,000+ pediatrics in the US alone. With a solid track record in medical device indications and positive pre-clinical evidence, Turn Therapeutics has the potential for significant growth in the biotech sector.

Bear case

Turn Therapeutics is facing several challenges and uncertainties due to their high reliance on their proprietary platform technology and the ongoing development and testing of their program GX-03. Additionally, their focus on developing non-systemic topical immunomodulators for inflammatory skin disease may limit their potential market and pricing capabilities. With a large but under-treated market for onychomycosis, there is potential for premium pricing for their product, but their limited access and availability may lead to lower adoption rates and chronic disease persistence. Despite a potential increase in price assumption for their product, the company still faces expenses and liabilities, causing concerns about their financial stability and success in the long run.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.